化合物SC99 T8719

Product Introduction
Bioactivity


英文名: SC99

描述: SC99 是一种口服有效选择性STAT3抑制剂，靶向 JAK2-STAT3 途径，抑制血小板活化和聚集，有抗骨髓瘤和抗血栓活性。它结合在 JAK2 的 ATP 结合袋中，抑制 JAK2 和 STAT3 的磷酸化。

体外活性: SC99 inhibited the phosphorylation of JAK2 and STAT3 in human platelets but had no effects on the phosphorylation of AKT, p65 or Src, all of which are involved in platelet activation.?SC99 inhibited human platelet aggregation induced by collagen and thrombin in a dose-dependent manner.?SC99 inhibited thrombin-induced P-selectin expression and fibrinogen binding to single platelets.?Moreover, SC99 inhibited platelet spreading on fibrinogen and clot retraction mediated by outside-in signaling.?SC99 inhibited platelet aggregation in mice but it did not significantly prolong the bleeding time.?SC99 inhibited platelet activation and aggregation as a STAT3 inhibitor.?This agent can be developed as a promising treatment for thrombotic disorders.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 82 mg/mL (243.94 mM)


关键字: orally | ERK | c-Src | ATP-binding | phosphorylation | platelet | AKT | Janus kinase | activation | SC-99 | anti-myeloma | mTOR | anti-thrombotic | Inhibitor | myeloma | SC99 | pocket | multiple | aggregation | STAT | OPM2 | JAK | SC 99 | Apoptosis | inhibit

相关产品: Citronellyl acetate | Methyl 3,4-dihydroxybenzoate | PP121 | Poncirin | Phytohemagglutinin | Sodium Oxamate | PI3K/Akt/mTOR-IN-2 | Kinetin riboside | Mitotane | 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(4-(4-cyanophenoxy)phenyl)urea

相关库: Anti-Prostate Cancer Compound Library | Anti-Liver Cancer Compound Library | Anti-Cancer Compound Library | Angiogenesis related Compound Library | Cancer Cell Differentiation Compound Library | Bioactive Compounds Library Max | Inhibitor Library | Kinase Inhibitor Library | Orally Active Compound Library | Covalent Inhibitor Library

化合物SC99 T8719信息由TargetMol中国为您提供，如您想了解更多关于化合物SC99 T8719报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途